Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit

Rhea-AI Summary

Jounce Therapeutics, Inc. (NASDAQ: JNCE) announced participation in a fireside chat at the Cowen 2020 IO Next Summit on November 13, 2020, at 12:15 p.m. ET. A live webcast of the session will be available on the company's website, with a replay archived for 30 days. Jounce focuses on developing novel cancer immunotherapies, including its lead candidate, vopratelimab, currently in the SELECT Phase 2 trial. The company is also advancing JTX-4014 and JTX-8064, and has licensed JTX-1811 to Gilead Sciences. For details, visit www.jouncetx.com.

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Cowen 2020 IO Next Summit on Friday, November 13, 2020 at 12:15 p.m. ET.

A live webcast of the presentation will be available by visiting "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

About Jounce Therapeutics:

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the SELECT trial and with Jounce’s broader pipeline. Jounce’s next development stage product candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. A Phase 1 trial evaluating JTX-8064 is planned to begin enrollment in the fourth quarter of 2020. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contacts:
Malin Deon
Jounce Therapeutics, Inc.
+1-857-259-3843
mdeon@jouncetx.com

Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com

FAQ

What is the date and time of Jounce Therapeutics' fireside chat at the Cowen 2020 IO Next Summit?

Jounce Therapeutics will participate in the fireside chat on November 13, 2020, at 12:15 p.m. ET.

Where can I watch the Jounce Therapeutics fireside chat?

The fireside chat will be available via a live webcast on Jounce's website under 'Events & Presentations'.

What is the focus of Jounce Therapeutics?

Jounce Therapeutics is focused on developing novel cancer immunotherapies and predictive biomarkers.

What are the key product candidates of Jounce Therapeutics?

Jounce's key product candidates include vopratelimab, JTX-4014, and JTX-8064.

What is the current status of vopratelimab?

Vopratelimab is currently being studied in the SELECT Phase 2 trial.